90 related articles for article (PubMed ID: 10806735)
1. [The clinical features and management of borderline ovarian tumors].
Zhang Z; Hong W; Li L
Zhonghua Fu Chan Ke Za Zhi; 1998 Sep; 33(9):556-9. PubMed ID: 10806735
[TBL] [Abstract][Full Text] [Related]
2. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
3. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
Poncelet C; Fauvet R; Yazbeck C; Coutant C; Darai E
Eur J Surg Oncol; 2010 Nov; 36(11):1066-72. PubMed ID: 20817462
[TBL] [Abstract][Full Text] [Related]
4. Borderline ovarian tumors: features and controversial aspects.
Messalli EM; Grauso F; Balbi G; Napolitano A; Seguino E; Torella M
Eur J Obstet Gynecol Reprod Biol; 2013 Mar; 167(1):86-9. PubMed ID: 23219291
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and pathological features of borderline ovarian tumors].
Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
[TBL] [Abstract][Full Text] [Related]
6. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
7. [The treatment of borderline ovarian tumors and its prognosis].
Li ZX; Qiu XF
Zhonghua Fu Chan Ke Za Zhi; 1994 Apr; 29(4):207-9, 251-2. PubMed ID: 8082441
[TBL] [Abstract][Full Text] [Related]
8. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
9. [Ovarian tumors of low malignant potential (borderline ovarian tumors)].
Luchian AM; Pricop M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):438-45. PubMed ID: 21870737
[TBL] [Abstract][Full Text] [Related]
10. Management of borderline ovarian tumors.
Tîrnovanu MC; Amancei S; Dumitrescu A; Onofriescu M; Dumitraşcu I
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1069-75. PubMed ID: 23700890
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
12. Borderline tumors of the ovary.
Damak T; Ben Hassouna J; Chargui R; Gamoudi A; Hechiche M; Dhieb T; Rahal K
Tunis Med; 2014 Jun; 92(6):411-6. PubMed ID: 25741843
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
14. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
15. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies.
Camatte S; Morice P; Atallah D; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Castaigne D
J Am Coll Surg; 2002 Sep; 195(3):332-8. PubMed ID: 12229940
[TBL] [Abstract][Full Text] [Related]
16. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
17. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
18. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
20. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
